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Abstract
Objective
To determine whether classes of diabetes medications are associated with cognitive health
and dementia risk, above and beyond their glycemic control properties.
Research design and methods
Findings were pooled from 5 population-based cohorts: the Framingham Heart Study, the
Rotterdam Study, the Atherosclerosis Risk in Communities (ARIC) Study, the Aging Gene-
Environment Susceptibility-Reykjavik Study (AGES) and the Sacramento Area Latino Study
on Aging (SALSA). Differences between users and non-users of insulin, metformin and sul-
fonylurea were assessed in each cohort for cognitive and brain MRI measures using linear
regression models, and cognitive decline and dementia/AD risk using mixed effect models
and Cox regression analyses, respectively. Findings were then pooled using meta-analytic
techniques, including 3,590 individuals with diabetes for the prospective analysis.
Results
After adjusting for potential confounders including indices of glycemic control, insulin use
was associated with increased risk of new-onset dementia (pooled HR (95% CI) = 1.58
PLOS ONE | https://doi.org/10.1371/journal.pone.0212293 February 15, 2019 1 / 18
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Weinstein G, Davis-Plourde KL, Conner S,
Himali JJ, Beiser AS, Lee A, et al. (2019)
Association of metformin, sulfonylurea and insulin
use with brain structure and function and risk of
dementia and Alzheimer’s disease: Pooled analysis
from 5 cohorts. PLoS ONE 14(2): e0212293.
https://doi.org/10.1371/journal.pone.0212293
Editor: Antony Bayer, Cardiff University, UNITED
KINGDOM
Received: November 10, 2018
Accepted: January 30, 2019
Published: February 15, 2019
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was supported by a grant from
the Alzheimer’s Drug Discovery Foundation
(contract number 20150702). Work on the SALSA
study for this was supported by NIA AG12975. The
Atherosclerosis Risk in Communities study has
been funded in whole or in part with Federal funds
from the National Heart, Lung, and Blood Institute,
(1.18, 2.12);p = 0.002) and with a greater decline in global cognitive function (β = -0.014
±0.007;p = 0.045). The associations with incident dementia remained similar after further
adjustment for renal function and excluding persons with diabetes whose treatment was life-
style change only. Insulin use was not related to cognitive function nor to brain MRI mea-
sures. No significant associations were found between metformin or sulfonylurea use and
outcomes of brain function and structure. There was no evidence of significant between-
study heterogeneity.
Conclusions
Despite its advantages in controlling glycemic dysregulation and preventing complications,
insulin treatment may be associated with increased adverse cognitive outcomes possibly
due to a greater risk of hypoglycemia.
Introduction
Dementia is a devastating clinical diagnosis that has physical, financial and social conse-
quences for patients, their care-givers and families, including increased mortality and a greater
need for medical services [1]. It is increasingly recognized that dementia is a life-course illness,
preceded by years and even decades of subclinical brain changes [2], which could explain why
later life disease-modifying treatments are ineffective for most people who already have
dementia [3]. A major risk factor for dementia and Alzheimer’s disease (AD) is type 2 diabetes
[4]. Even in persons free of clinical dementia, diabetes is associated with poor cognitive perfor-
mance [5, 6] and with increased brain atrophy [5, 7].
Pharmacological treatment options for type 2 diabetes have been available for several
decades, and are generally regarded as safe and well tolerated [8]. The aim of these therapies is
to reduce and maintain glucose concentrations as close to normal for as long as possible after
diagnosis. In turn, glycemic control is efficient in reducing micro- and macrovascular compli-
cations [9], including a modest reduction of 15% in risk of myocardial infarction and 13%
reduction in all-cause mortality [10]. Yet, while type 2 diabetes may increase both AD neuro-
pathology and cerebral infarcts in the brain [11], it is unclear whether this process can be pre-
vented or delayed with tight glycemic control [12].
Diabetes drugs’ mechanisms of action involve multiple pathologies common to diabetes
and dementia and AD, including insulin resistance and impaired glucose metabolism [13].
Thus, there is an intense interest in whether type 2 diabetes drugs can be repurposed to slow
cognitive aging and reduce the risk of cognitive impairment and dementia through direct
effects in the brain that are independent of their approved indications for treating high blood
glucose [14]. In contrast, type 2 diabetes medications may also have detrimental effects on the
brain, possibly through their tendency to cause hypoglycemic episodes [15, 16].
To date, only few clinical and observational studies have been done to assess the relation-
ship of diabetes medications and cognitive health, and existing findings are inconsistent [17,
18]. Furthermore, it remains to be clarified whether a possible protective role is independent
from the glycemic control properties of the drugs. Thus, the aim of the current study is to test
whether use of insulin, sulfonylureas and metformin are associated with cognitive perfor-
mance, cognitive decline, MRI measures and risk of dementia and AD, above and beyond
their glycemic control properties.
Diabetes drugs, brain aging and dementia
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Methods
Study population
The study is based on data from the following cohorts: The Offspring cohort of the Framing-
ham Heart Study (FHS) [19, 20], the Rotterdam Study (RS) [21], the Atherosclerosis Risk in
Communities (ARIC) Study,[22] the Aging Gene-Environment Susceptibility-Reykjavik Study
(AGES) [23] and the Sacramento Area Latino Study on Aging (SALSA) [24]. The Israel Diabe-
tes and Cognitive Decline study (IDCD) [25] contributed cross-sectional results for the cogni-
tive function and MRI outcomes. Each of these cohorts is a large-scale, community based,
longitudinal study, in which assessment of the link between impairment in glucose homeosta-
sis and neurological outcomes is a primary goal.
The study samples included only participants with a diagnosis of diabetes. The definition of
diabetes in each cohort is presented in S1 Table. In FHS, ARIC and SALSA, visits from which
samples were drawn differed between the cross-sectional and prospective analyses (Table 1),
because we attempted to choose the most appropriate visits for these analyses with regard to
the extent of details on number of medications and duration of follow-up.
Use of diabetes medications
We first assessed the distribution of medication use according to specific classes available on
the market, as well as medications being used in combination (S2 Table). We focused on
Table 1. Study characteristics of participants.
Prospective analysis: incident dementia and AD (baseline characteristics)
FHS AGES SALSA ARIC RS IDCD
Year of inception Offspring cohort exam 7 (1998–2001) AGES II (2007–2011) 1998 Visit 4 (1996–1998) 2004–2008 N/A
N 301 623 586 1,197 608 N/A
Mean age (years) 70.1 ± 5.9 76.4±5.3 69.9±6.6 64.0±5.8 63.6±7.8 N/A
N (%) women 123 (44.4) 285 (45.8%) 313 (56.4) 646(54.0) 274 (45.1) N/A
Duration of follow-up (years) 7.5±4.8 5.2±0.2 5.3±3.1 12.3±4.4 6.4±2.5 N/A
Incident dementia, N (%) 38 (13.7) 27 (8.1) 55 (9.4) 198 (11.24) 31 (5.1) N/A
Incident AD, N (%) among diabetics 30 (10.8) 20 (6) 32 (5.5) N/A 16 (2.7) N/A
Cross-sectional analysis: cognition
FHS AGES SALSA ARIC RS IDCD
Visit (years) Offspring cohort exam 8 (2005–2008) AGES I (2002–2006) 1998–1999 visit 5 (2011–2013) 2004–2008 2010–2012
N 322 694 586 1,732 451 912
Mean age (years) 70±9 77±6 70±7 76±5 63±8 73±5
N (%) women 127 (39.4) 3,166 (57) 332 (56.7) 981 (57) 199 (44) 539 (59)
Longitudinal analysis: cognition (baseline characteristics; including prevalent dementia cases)
FHS AGES SALSA ARIC RS IDCD
Baseline visit (years) Offspring cohort exam 7 (1998–2001) AGES I (2002–2006) 1998–1999 Visit 4 (1996–1998) 2004–2008 N/A
N 194 287 586 1,197 250 N/A
Mean age (years) 64±9 75±4 70±7 64±6 61±7 N/A
N (%) women 80 (41) 134 (46.7) 332 (56.7) 646 (54.0) 103 (41.2) N/A
Cross-sectional analysis: brain MRI measures
FHS AGES SALSA ARIC RS IDCD
Visit (years) Offspring cohort exam 8 (2005–2008) AGES I (2002–2006) 1998–1999, 2002 visit 5 (2011–2013) 2004–2008 2010–2012
N 234 N/A 85 575 349 125
Mean age (years) 69±8 N/A 71±7 76±5 61±8 72±4
N (%) women 86 (36.8) N/A 46 (54.1) 340 (59) 144 (41.3) 48 (38)
https://doi.org/10.1371/journal.pone.0212293.t001
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metformin, sulfonylurea and insulin because use of these medication classes was common at
time of studies’ baseline (in contrast to other drug classes such as DPP-4 enzyme inhibitor,
Meglitinide).
Definition of dementia and AD
Information on incident dementia was available from FHS, RS, ARIC, AGES and SALSA. Inci-
dent AD was available from FHS, RS, AGES and SALSA. Dementia was defined using the
Diagnostic and Statistical Manual of Mental Disorders revised third or fourth edition
(DSM-IIIR or DSM-IV) criteria [f1]. AD was defined using the National Institute of Neurolog-
ical and Communicative Disorders and Stroke and AD and Related Disorders Association
(NINCDS-ADRDA) criteria, and included persons with definite (diagnosis of AD patholog-
ically confirmed at autopsy), probable or possible AD [26]. Incident dementia was adjudicated
in each study and was based on hospitalization, dementia diagnosed at study visits and demen-
tia coded on the death certificate. Durations of follow-up ranged between 5.2 years (in AGES)
and 12.3 years (in ARIC) (Table 1).
MRI
Years of brain MRI examinations and number of individuals with available MRI scans in each
study are presented in Table 1. MRI scans were performed and interpreted in a standardized
fashion in each study, blind to subjects‘clinical or demographic information. Details on MRI
parameters and phenotype definition are provided elsewhere [27, 28]. Briefly, automated or
semi-quantitative post-processing software was used to measure intracranial volume and total
brain volume. Hippocampal volume was evaluated using operator-defined boundaries drawn
on serial coronal sections or automated methods [29].
WMH burden was estimated on a quantitative scale using custom-written computer pro-
grams in AGES, FHS, and RS; in ARIC, CHS and SALSA, WMH burden was estimated on a
semi-quantitative scale [30]. As well, total brain volume, hippocampal volume and white mat-
ter hyperintensity volume were expressed as percentage of intracranial volume to correct for
differences in head size. White matter hyperintensity volume was log-transformed to account
for skewness.
Cognitive function
General cognition- Cohorts used different neuropsychological batteries. Therefore, for the
current analyses, each cohort created a global cognitive score based on its available cognitive
tests (S1 and S3 Tables). The global score was the first score on the unrotated principal compo-
nent on a principal component analysis forcing a single score solution (PC1). Measures that
had a skewed distribution were natural log-transformed, and directionality was reversed such
that higher scores reflect superior performance. It has been previously shown that despite the
heterogeneity in cognitive test batteries, individual differences on the general cognitive com-
ponent are negligible [31]. To further validate the global cognitive components, we confirmed
that their univariate associations with age, sex, education and hypertension prevalence were
similar across cohorts.
Executive function was assessed using differences in time to complete the trails-making B
and the trails-making A tests (TrB-TrA) in FHS, ARIC and IDCD. Digit span backwards was
used in AGES and IDCD.
Memory was ascertained using word-list and paragraph recall tests. The average score on
immediate and delayed recall was used as well as the delayed recall score on each test.
Diabetes drugs, brain aging and dementia
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Performance on executive function and memory were expressed as cohort specific z-scores
(test scores transformed to mean zero and standard deviation one).
Potential confounders
Educational achievement was defined as a four-class variable (no high-school degree, high-
school degree only, some college and at least a college degree) in all cohorts. Physical activity
was ascertained as study-specific tertiles due to heterogeneity in methodology used to assess
this variable across cohorts. Smokers were those who currently smoked vs. others (former or
never-smokers). Hypertension was defined as a dichotomous variable according to the JNC-8
criteria in SALSA and JNC-7 criteria in the other cohorts, with “yes” being stage 1 hyperten-
sion defined as> = 140 mmHg for systolic or> = 90 mmHg for diastolic blood pressure or on
medications. Cardiovascular diseases included the following conditions: coronary heart dis-
ease, congestive heart failure, myocardial infarction, angina pectoris and coronary insuffi-
ciency. Prevalent stroke was defined as an acute onset focal neurological deficit of presumed
vascular pathogenesis lasting�24 hours. All stroke subtypes were included except transient
ischemic attacks (TIAs) (i.e. Cerebrovascular accident, atherothrombotic infarction, Cerebral
Embolism, Intracerebral. Hemorrhage and Subarachnoid Hemorrhage). Body mass index
(BMI) was defined by weight (in kilograms) divided by the square of height (in meters). This
variable was log-transformed and used as continuous and in all but in SALSA, in which 3 cate-
gories with cutoffs at 25 and 30 were used. Depression was defined as a score of 16 or higher
on the Center for Epidemiologic Studies Depression Scale (CES-D) in FHS, SALSA and RS. In
ARIC, the shortened form was used hence depression was defined if score was 9 or higher. In
AGES and IDCD depression was ascertained using the geriatric depression scale (GDS) with a
cutoff at 10. ApoE4 carriership was defined as having at least one ε4 allele. Glycemic control
indices were chosen as follows: Hemoglobin A1C (HbA1C) was used in FHS, AGES and ARIC
studies, but was not available in SALSA (at baseline) or in RS. Thus, blood glucose was used as
a measure of glycemic control. Tests for blood glucose were done in fasting and random states
in SALSA and RS, respectively.
Statistical analysis
Users of each of metformin, sulfonylurea and insulin drug classes, as a single therapy or in
combination with other treatments, were compared to non-users of the specific class. All anal-
yses were performed separately in each cohort and then pooled using meta-analytical
techniques.
In the cross-sectional analyses, we assessed the relationships of each of metformin, sulfonylurea
and insulin use with global (PC1), domain-specific cognitive scores and brain MRI measures
using linear regression models. Any measure with skewed distribution was log-transformed and
directionality was reversed such that higher scores reflect better performance.
The associations between medication use and change in global cognitive function were
assessed using linear mixed models, with random slope and intercept, and including an inter-
action term between the treatment group and time between cognitive evaluations. In each
cohort, participants were included if they had two cognitive assessments or more. Cognitive
change was assessed using the difference between two PC1 measurements: the first was evalu-
ated from a baseline visit and the second was the last PC1 available from follow-up examina-
tions. Although information on more than two cognitive evaluations was available for most
studies, we chose to use only the first and last ones to avoid bias due to multiple cognitive test-
ing among individuals who are suspected for cognitive impairment. Follow-up PC1 was stan-
dardized using the same mean and standard deviation as the baseline PC1 to ensure that
Diabetes drugs, brain aging and dementia
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changes in standardized PC1 were due to changes in cognition and not due to differences in
the mean and standard deviation between baseline and follow-up. All analyses were first con-
ducted including individuals with prevalent dementia, and then excluding them in secondary
analyses.
The relationships between diabetes treatment and incident dementia and AD were assessed
using multivariable Cox proportional hazard models using time on study as the time scale. For
these analyses, each study excluded prevalent dementia/AD at baseline.
Models were adjusted first for age, sex, education (except for MRI outcomes), interval
between exam cycles and cognitive/MRI examination (except for cognitive change outcomes),
then additionally for physical activity, hypertension, cardiovascular disease, stroke, total cho-
lesterol, smoking, depression, and BMI. In a subsequent model we also controlled for HbA1C
or fasting or random blood glucose (depending on cohort-specific data availability) and
ApoE4. To reduce risk for indication bias we conducted several secondary analyses as follows:
first, we excluded subjects with DM who do not take DM medications. Second, post-hoc analy-
ses were done to assess the relationship of further potential confounders with DM medication
use. eGFR was found to be strongly associated with indication in most studies. Therefore, the
models relating DM drug class to incident dementia and AD have also been adjusted for
eGFR. Lastly, we added diabetes duration as another potential confounder in our models, but
this analysis was restricted to participants from the ARIC study where this variable was
available.
Meta-analysis
Study-specific beta-estimates and log hazard ratios (later exponentiated) were combined into
pooled values with 95% confidence intervals. The I2 statistic, representing the percentage of
the variability in risk estimates that is caused by heterogeneity rather than chance was
employed to quantify heterogeneity [32]. Summary results were thought to be substantial het-
erogeneity if I2>0.75. In the presence of low heterogeneity, we used fixed-effect models; how-
ever, random-effect models, which consider heterogeneity across cohorts and consequently
yield more conservative pooled results were additionally performed as a secondary analysis.
Results
The total number of participants was 3,590 in the prospective dementia/AD analysis, 4,697
and 2,514 were available for the cross-sectional and longitudinal cognitive performance analy-
ses, respectively, and 1,243 were available for the brain MRI outcomes. Participant characteris-
tics are presented for each cohort and separately for the prospective and cross-sectional
analyses (Table 1 and S4 Table). Mean ages ranged between 64±8 years (in RS) and 76±5 years
(AGES) for incident dementia outcomes, between 63±8 years (in RS) and 77±6 years (AGES)
for the cognitive outcomes and between 61±8 years (in RS) and 76±5 years (in ARIC) for the
MRI outcomes (Table 1).
Incident dementia and AD
Overall, formal tests for heterogeneity showed no statistically significant heterogeneity across
cohorts (S5 Table). Therefore, fixed-effect models were primarily used to pool Hazard Ratios
(HRs).
Compared to individuals with diabetes who did not use insulin, those who did had an
increased risk for dementia independently of multiple potential confounders, including
depression and HbA1C or Glucose levels (HR(95% CI) = 1.58 (1.18, 2.12); p = 0.002, Table 2,
model 3 and Fig 1). No significant associations between insulin use and AD risk were
Diabetes drugs, brain aging and dementia
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Table 2. Associations of diabetes drug classes (single or in combination) with risk of dementia/AD among individuals with diabetes- fixed effects meta-analysis.
Metformin Sulfonylurea Insulin
Outcome # cohorts HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Model 1
Incident AD 4 1.37 (0.83, 2.27) 0.222 0.91 (0.59, 1.41) 0.677 1.61 (0.90, 2.89) 0.112
Incident Dementia 5 1.26 (0.94, 1.7) 0.125 0.97 (0.78, 1.22) 0.800 1.61 (1.23, 2.11) <0.001
Model 2
Incident AD 4 1.62 (0.92, 2.85) 0.097 0.98 (0.6, 1.6) 0.927 1.42 (0.67, 3) 0.358
Incident Dementia 5 1.35 (0.98, 1.85) 0.065 0.97 (0.77, 1.23) 0.828 1.56 (1.17, 2.08) 0.002
Model 3
Incident AD 4 1.61 (0.89, 2.9) 0.116 1.04 (0.62, 1.74) 0.871 1.28 (0.56, 2.93) 0.556
Incident Dementia 5 1.36 (0.98, 1.89) 0.063 0.98 (0.77, 1.24) 0.853 1.58 (1.18, 2.12) 0.002
Model 4
Incident AD 4 1.60 (0.87, 2.93) 0.131 0.9 (0.52, 1.57) 0.712 1.24 (0.53, 2.88) 0.616
Incident Dementia 5 1.42 (1.02, 1.98) 0.038 0.98 (0.77, 1.26) 0.894 1.54 (1.14, 2.07) 0.005
AD = Alzheimer’s Disease. Model 1 is adjusted for age, sex and education. Model 2 is additionally adjusted for Physical activity, hypertension, CVD, stroke, total
cholesterol, smoking, depression and BMI. Model 3 is additionally adjusted for HbA1C, ApoE4. Model 4 is additionally adjusted for eGFR.
https://doi.org/10.1371/journal.pone.0212293.t002
Fig 1. Association between insulin use and dementia risk. Comparison was made between users of insulin as a single drug or in combination with other
diabetic drugs and non-users of insulin.
https://doi.org/10.1371/journal.pone.0212293.g001
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identified. The associations between insulin use and incident dementia remained significant
after additional adjustment for eGFR (HR (95% CI) = 1.54 (1.14, 2.07) (Table 2), after exclud-
ing from the comparison group individuals with diabetes who were not on any diabetes medi-
cation (HR (95% CI) = 1.49 (1.07, 2.07) (S6A Table) and when random rather than fixed-
effects meta-analysis was used (HR (95% CI) = 1.54 (1.14, 2.07) and HR (95% CI) = 1.55 (1.12,
2.15) among diabetes patients and users of diabetes medications, respectively (S7A and S7B
Table). In analyses restricted to participants from the ARIC study, additional adjustment for
diabetes duration attenuated the associations: HRs (95% CI) went down from 1.61 (1.15,2.26)
to 1.31 (0.90,1.92) for all persons with diabetes, and from 1.42 (0.98,2.07) to 1.34 (0.89,2.01) for
those who received diabetes treatment.
Overall, sulfonylurea use vs. non-use was not significantly associated with risk for dementia
or AD (Table 2 and S6A, S7A and S7B Tables). An exception was a decreased dementia risk
associated with sulfonylurea use but only when the sample was restricted to those who take
diabetes medications (HR (95% CI) = 0.64 (0.46, 0.88); p = 0.007) (S6A Table; model 4), and in
the fixed but not the random effect models (S7A and S7B Table). Risk of dementia among Met-
formin users compared to non-users was increased, however statistically significance was
apparent only after adjustment for the study’s covariates including kidney function (HR (95%
CI) = 1.42 (1.02, 1.98); p = 0.038) (Table 2; model 4).
Cognitive performance, cognitive change and brain MRI measures
After adjustment for the study’s covariates, no significant association was observed between
metformin, sulfonylurea or insulin use and global or test-specific cognitive function (Table 3
and S6B, S7C and S7D Tables).
Some evidence of a greater decline in global cognitive performance was observed in those
who use sulfonylurea compared to those who use other medications or life-style change
(Table 4). However, these associations were no longer significant after excluding individuals
with prevalent dementia at baseline (Table 4), after excluding those who are on life-style
change only (S6C Table) or when random effect models were used (S7E and S7F Table).
Lastly, a significant association was identified between sulfonylurea use and smaller total
brain volume after adjusting for potential confounders (β = -0.007±0.003; p = 0.037) (Table 5).
Nevertheless, these associations were no longer significant after excluding individuals with
prevalent dementia (Table 5), after excluding participants with diabetes who do not take diabe-
tes medications (S6D Table), and when random effect meta-analyses were used (S7G and S7H
Table).
Discussion
The main findings from this 5-cohorts pooled analysis of 3,590 individuals with diabetes, is
that using insulin was associated with 50% increased dementia risk compared to using other
treatments for diabetes. In addition, metformin and sulfonylurea use was not associated with
dementia risk nor with other measures of cognitive aging.
Administration of exogenous insulin (through controlled infusion while maintaining con-
stant glucose levels [33] or through intranasal administration) has been suggested as a promis-
ing therapeutic approach against dementia and AD. Particularly, intranasal administration of
insulin has shown promising results in slowing brain aging and improving cognitive function
among demented individuals [34, 35], although various modifying effects such as by ApoE
genotype and dosing need to be elucidated [36, 37]. These findings are supported by basic
research, showing that insulin exerts various neuromodulatory actions in the brain with impli-
cations on cognitive function and neurodegeneration, including synaptic formation and
Diabetes drugs, brain aging and dementia
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Table 3. Associations of diabetes drug classes (single or in combination) with cognitive performance among individuals with diabetes- fixed effects meta-analysis
(dementia cases are included).
Metformin Sulfonylurea Insulin
Outcome # cohorts Estimate SE p-value Estimate SE p-value Estimate SE p-value
Model 1
Global cognition 6 -0.030 0.027 0.256 -0.075 0.029 0.010 -0.190 0.038 <0.001
Executive function (trails B-A) 3 -0.043 0.036 0.238 -0.079 0.044 0.070 -0.110 0.055 0.047
Executive function (digit span backwards) 2 -0.077 0.053 0.148 -0.078 0.061 0.206 -0.036 0.102 0.721
Word list - delayed 5 -0.013 0.029 0.664 -0.027 0.032 0.393 -0.084 0.041 0.043
Word list - combined 4 -0.046 0.039 0.242 -0.019 0.041 0.644 -0.003 0.059 0.956
Paragraph recall - delayed 3 0.042 0.034 0.226 -0.012 0.040 0.760 -0.076 0.049 0.117
Paragraph recall - combined 3 0.057 0.034 0.097 0.003 0.040 0.941 -0.075 0.049 0.126
Model 2
Global cognition 6 -0.049 0.027 0.068 -0.073 0.029 0.014 -0.110 0.038 0.004
Executive function (trails B-A) 3 -0.044 0.037 0.237 -0.072 0.045 0.113 -0.085 0.058 0.144
Executive function (digit span backwards) 2 -0.077 0.054 0.154 -0.047 0.066 0.476 0.012 0.103 0.907
Word list - delayed 5 -0.030 0.030 0.317 -0.019 0.033 0.555 -0.054 0.043 0.216
Word list - combined 4 -0.037 0.039 0.348 0.002 0.041 0.965 0.069 0.059 0.245
Paragraph recall - delayed 3 0.019 0.036 0.592 -0.042 0.043 0.325 -0.036 0.053 0.499
Paragraph recall - combined 3 0.034 0.036 0.339 -0.025 0.042 0.548 -0.029 0.053 0.579
Model 3
Global cognition 6 -0.030 0.027 0.274 -0.045 0.030 0.137 -0.034 0.041 0.400
Executive function (trails B-A) 3 -0.031 0.040 0.445 -0.050 0.049 0.304 -0.005 0.063 0.933
Executive function (digit span backwards) 2 -0.087 0.054 0.106 -0.028 0.066 0.671 0.051 0.108 0.637
Word list - delayed 5 -0.027 0.031 0.379 -0.011 0.034 0.739 -0.019 0.046 0.676
Word list - combined 4 -0.046 0.040 0.247 -0.005 0.042 0.908 0.075 0.060 0.215
Paragraph recall - delayed 3 0.024 0.037 0.507 -0.036 0.045 0.418 0.002 0.058 0.974
Paragraph recall - combined 3 0.036 0.036 0.328 -0.019 0.044 0.659 0.007 0.058 0.902
Model 1: Age, sex, education and interval between exam cycle and the NP assessment. Model 2: Model 1 + Physical activity, hypertension, CVD, stroke, total cholesterol,
smoking, depression, BMI. Model 3: Model 2+HbA1C/ fasting blood glucose /random state blood glucose and ApoE4.
https://doi.org/10.1371/journal.pone.0212293.t003
Table 4. Associations of diabetes drug classes (single or in combination) with change in global cognition among individuals with diabetes- Fixed effects meta-
analysis.
Metformin� Sulfonylurea Insulin
Model # cohorts Estimate SE p-value Estimate SE p-value Estimate SE p-value
Including prevalent dementia
1 5 0.005 0.007 0.526 -0.02 0.005 0.047 -0.007 0.007 0.269
2 5 0.004 0.008 0.634 -0.011 0.005 0.043 -0.009 0.007 0.197
3 5 0.004 0.008 0.650 -0.012 0.005 0.034 -0.011 0.007 0.132
Excluding prevalent dementia
1 5 0.003 0.007 0.728 -0.007 0.005 0.200 -0.012 0.007 0.068
2 5 0.002 0.008 0.771 -0.008 0.005 0.160 -0.013 0.007 0.062
3 5 0.002 0.008 0.827 -0.009 0.006 0.109 -0.014 0.007 0.045
Model 1: age, sex and education. Model 2: further adjustment for physical activity, hypertension, CVD, stroke, total cholesterol, smoking, depression, and BMI. Model 3:
Further adjustment for HbA1C/ fasting blood glucose /random state blood glucose and ApoE4.
https://doi.org/10.1371/journal.pone.0212293.t004
Diabetes drugs, brain aging and dementia
PLOS ONE | https://doi.org/10.1371/journal.pone.0212293 February 15, 2019 9 / 18
remodeling, regulation of neurotransmitters, amyloid clearance, and tau phosphorylation [38].
In contrast to these neuroprotective effects, peripheral insulin administration to achieve glyce-
mic control in diabetic patients may have distinct consequences. In line with our findings, a
recent case-control study demonstrated a positive association between insulin use and demen-
tia risk [18]. Peripheral insulin use may result in deleterious effects to the brain, due to its ten-
dency to induce hypoglycemia. Indeed, episodes of hypoglycemia has been long associated
with increased risk of dementia in many [16, 39], although not all [40, 41] studies. In the pro-
spective population-based Health, Aging, and Body Composition study, a bidirectional associ-
ation has been demonstrated between hypoglycemia and dementia risk among 783 older
adults, with an estimated 2-fold increase in dementia risk among individuals who experienced
hypoglycemic episodes compared to those who did not [42]. Postulated underlying mecha-
nisms include metabolic insult as a consequence of brain mitochondrial dysfunction and
increased oxidative stress in the brain [43–45]. Although information on hypoglycemic epi-
sode was not available in our samples, others have shown that the overall incidence of hypogly-
cemia requiring medical intervention among adults with type 2 diabetes is considerable, and is
strongly linked with insulin use [46]. Numbers of hypoglycemic episodes is much larger if
mild-to-moderate episodes are considered [47], however the extent of their association with
dementia risk is unclear.
Insulin use was associated with risk of dementia but not AD. In addition, the attenuation in
effect sizes after controlling for potential covariates was greater when the outcome was inci-
dent AD rather than incident dementia. This may indicate that vascular mechanisms underlie
Table 5. Associations of diabetes drug classes (single or in combination) with brain MRI measures among individuals with diabetes- Fixed effects meta-analysis.
Metformin Sulfonylurea Insulin
Model Outcome # cohorts Estimate SE p-value Estimate SE p-value Estimate SE p-value
Including prevalent dementia
1 TCBV 5 -0.003 0.002 0.189 -0.010 0.003 <0.001 -0.012 0.004 0.005
HPV 5 0.00001 0.00001 0.318 0.000003 0.00001 0.766 -0.00002 0.00002 0.315
WMHV 6 0.062 0.038 0.105 0.077 0.044 0.083 0.144 0.060 0.016
2 TCBV 5 -0.002 0.002 0.389 -0.008 0.003 0.014 -0.011 0.004 0.011
HPV 5 0.00001 0.00001 0.318 0.000002 0.00001 0.843 -0.00002 0.00002 0.315
WMHV 6 0.037 0.0382 0.339 0.046 0.045 0.301 0.062 0.058 0.280
3 TCBV 5 -0.001 0.002 0.632 -0.007 0.003 0.037 -0.008 0.004 0.054
HPV 5 0.00001 0.00001 0.318 0.00001 0.00001 0.318 -0.00001 0.00002 0.615
WMHV 6 0.030 0.039 0.444 0.034 0.045 0.447 0.040 0.060 0.509
Excluding prevalent dementia
1 TCBV 4 -0.005 0.003 0.0915 -0.011 0.003 <0.001 -0.009 0.006 0.154
HPV 4 -0.002 0.005 0.650 -0.006 0.005 0.255 -0.011 0.006 0.090
WMHV 5 0.0467 0.040 0.241 0.078 0.046 0.089 0.151 0.062 0.014
2 TCBV 4 0.004 0.003 0.188 -0.007 0.004 0.075 -0.006 0.006 0.357
HPV 4 -0.004 0.005 0.404 -0.005 0.006 0.396 -0.013 0.007 0.080
WMHV 5 0.0186 0.040 0.640 0.049 0.046 0.286 0.074 0.059 0.210
3 TCBV 4 -0.002 0.003 0.500 -0.008 0.006 0.170 -0.003 0.006 0.578
HPV 4 -0.002 0.005 0.6712 -0.003 0.006 0.636 -0.011 0.008 0.168
WMHV 5 0.012 0.041 0.775 0.041 0.046 0.374 0.0617 0.061 0.316
TCBV = Total cerebral brain volume; HPV = Hippocampal volume; WMHV = White matter hyperintensity volume. Model 1: age, sex and education. Model 2: further
adjustment for physical activity, hypertension, CVD, stroke, total cholesterol, smoking, depression, and BMI. Model 3: Further adjustment for HbA1C/ fasting blood
glucose /random state blood glucose and ApoE4.
https://doi.org/10.1371/journal.pone.0212293.t005
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these findings, as vascular dementia is the second most frequent dementia subtype after AD
[48]. Yet, it is important to note that results from the ARIC study were not included in the
pooled AD risk estimate, which may decrease statistical power to detect such an association.
In our meta-analysis results, metformin and sulfonylurea were not associated with mea-
sures of brain function and structure. Metformin, a Biguanide, reduces insulin-mediated
hepatic glucose production and increases peripheral glucose disposal [49]. In the context of
AD, metformin has been suggested as a potentially anti-AD treatment, partly due to its roles in
neuroprotection, in decreasing insulin resistance and prevention of AD-like pathological char-
acteristics [50, 51]. However, determinantal effects in terms of AD risk have also been demon-
strated in pre-clinical studies, where exacerbation of AD pathology has been shown [52]
together with possible mechanisms affecting brain damage [53]. Similarly, findings from epi-
demiologic research are conflicting, with some showing decreased risk of cognitive decline
[54] and dementia [55, 56] as well as improved cognitive performance [57, 58], while others
demonstrating no association of metformin use with cognitive outcomes [59] as in our study,
or even slightly increased AD risk [60].
Compared to metformin, mechanisms of sulfonylureas are less clear in general and particu-
larly in the context of brain health [61]. In addition, the associations of sulfonylurea with cog-
nitive outcomes have been rarely studied. Overall, we did not find associations with brain
health, which is consistent with most existing studies showing no associations with cognitive
function [57] and dementia risk [60, 62]. In contrast, we found some evidence of protective
effect when comparing sulfonylurea users to others who receive diabetic medications (exclud-
ing those on life-style change), in line with several other studies that suggest a neuroprotective
effect for sulfonylurea [55, 56].
The inconsistency between our findings and previous literature may stem from heterogene-
ity in study population, design and methodologies. One methodological difference worth not-
ing is the lack of some studies to adjust for measures of glycemic control [56, 57, 60], which
impair their ability to infer on the role of diabetes medication use per se (i.e. above and beyond
their role in controlling blood glucose levels). A recent study among elderly US veterans com-
pared dementia risk in 17,200 new users of metformin to 11,440 new users of sulfonylurea,
and found lower risk among metformin users in a subsample of veterans aged <75 years [62].
This study was retrospective, utilizing data from national Veterans Administration clinical and
administrative databases and Medicare, and therefore lacked information on education and
was prone to misclassification of key measures including dementia incidence and to ascertain-
ment bias. In contrast, our study combined data from prospective, population-based cohorts,
each of which carefully ascertained dementia cases and other important clinical and demo-
graphic information and may have better representation of the general population.
Observational studies are essential in assessing the link between medical treatments and
long-term cognitive health [14, 63]. While randomized controlled trials (RCTs) are considered
the best levels of evidence and are the only study design which can establish causality, their
role in understanding the relationships between diabetes medications and cognitive outcomes
is limited. Among other weaknesses, RCTs are often restricted by head-to-head comparisons
and short follow-up duration resulting in insufficient power to detect changes in cognitive
function or assessment of incipient dementia cases. Observational study designs can overcome
some of these problems and are “closer” to real world in terms of the heterogeneity of the
study sample. A major threat to observational studies assessing the comparative role of various
treatments on disease prevention is confounding by indication. In our study, the possibility
that our finding of increased dementia risk among insulin users compared to non-users is a
consequence of such bias cannot be excluded, as insulin treatment is usually given in advanced
phases of the disease, after life-style change and oral medications are no longer effective in
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controlling of blood glucose [64]. Indeed, among the participants from the ARIC study, the
associations between insulin use and dementia risk attenuated after additional adjustment for
diabetes duration. Nevertheless, the association of insulin use with dementia risk in the total
sample remained robust even after excluding individuals who are in their early phases of the
disease (not treated with medications), and after adjusting for measures of glycemic control
and eGFR. Of note, the latter is an important covariate as renal function correlates with dura-
tion of diabetes [65] and affects diabetes drug choice [66]. These results, together with the bio-
logical rationale of hypoglycemic episodes influences, imply that the increased dementia risk
among insulin users cannot be fully explained by indication bias.
Other limitations of the study are as follows: First, most participating cohorts did not have
data on diabetes duration, and therefore this variable was not included as a covariate. However,
diabetes duration is strongly correlated with eGFR [65] which was adjusted for in our models.
In addition, we were not able to assess the relationship of newer diabetes medication classes
with the study’s outcomes, as calendar times of assessments go back to times when these treat-
ments were not available. Lastly, individuals from the participating cohorts are predominantly
of European ancestry, yet it should be noted that ARIC study, which includes ~25% African-
Americans, drives much of the association between insulin use and incident dementia.
The study has several strengths worth mentioning: first, by pooling data from five large
cohorts we created a large group of individuals with prospectively ascertained diabetes, thus
optimized our power to detect associations which may otherwise could not be identified. In
addition, careful harmonization of variables between cohorts was conducted, and data was
analyzed according to pre-specified statistical analysis plans, which helped reduce heterogene-
ity across cohort-specific results. In addition, in contrast to data-pooling from published
works, our findings are not subjected to publication bias. Lastly, we adjusted for potential con-
founders including markers of disease severity and glycemic control, therefore we could assess
the possible roles of treatments in cognitive health beyond their glycemic control effects and
reduced the possibility of confounding by indication.
Our findings raise concern regarding increased dementia risk among middle-aged and old-
adults who use insulin. Future research is encouraged to investigate the possible mediation
role of hypoglycemic episodes in this association, and to identify modifiers which will enable
more personalized diabetes treatment to reduce dementia risk.
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